x

About Dr Lobo

Blood Pressure Expertise

Excellence in Clinical Practice

Dr Lobo is the Director of the internationally renowned Bart’s Blood Pressure Clinic which has been recognised as a Hypertension Centre of Excellence by the European Society of Hypertension and receives referrals of complex hypertensive patients on a national and international basis. The clinic is allied to the world renowned William Harvey Research Institute and has participated in several landmark studies in hypertension. These include the ground-breaking ASCOT study which led to a change in UK Hypertension guidelines as well as the Symplicity HTN-2 study of renal denervation for treatment-resistant hypertension1,2 and most recently the ROX Control Hypertension Study of a novel central iliac arteriovenous anastomosis to treat uncontrolled hypertension3.

Since October 2011 he has co-hosted and chaired the annual UK Symposia on Renal Denervation at the Royal College of Physicians with a distinguished panel of international authorities in hypertension medicine and interventionists.

Dr Lobo is a member of the Joint British Societies steering committee on renal denervation and author of the JBS Consensus Statements on Renal Denervation4,5. He has lectured and published extensively on hypertension and novel therapies of resistant hypertension6.

Research Excellence

Dr Lobo has developed three major research themes in thee Barts Blood Pressure Clinic which he leads on.

  1. Device therapy of Hypertension

    As Chief or Principal investigator of numerous studies in the field of resistant hypertension, Dr Lobo continues to strive to bring new therapies to the hypertension clinic which are safe and effective7-10.

  2. Phenotyping of complex hypertension

    Dr Lobo has set up an autonomic and cardiovascular haemodynamic laboratory to study the role of sympathetic nervous signalling in hypertension and circulatory regulation11.

  3. Multi-drug intolerant patients

    A further major interest of his group is in the management of patients with multiple drug intolerances who are unable to take conventional antihypertensive medications and thus pose a real challenge to clinicians. Exciting preliminary data from this cohort of patients indicates that a stratified medicines approach using fractional tablet dosing, liquid antihypertensives and patch formulations of antihypertensive drugs can achieve significant BP lowering in this high risk patient group.

Grants:

Dr Lobo has been awarded a £400 000 grant (from the Barts and The London Charitable Foundation) to study the effects of renal denervation on blood pressure and autonomic function in patients with chronic kidney disease and patients who are intolerant of anti-hypertensive medications.

Teaching Excellence

Dr Lobo is a highly regarded medical educator and teacher as evidenced by a number of teaching prizes and invitations to teach on prestigious courses as well as speaker engagements at key national and international conferences12.

  1. Teaching prizes
    • William Harvey Research Institute Prize for Teaching Excellence 2012
    • NHS Teachers Award 2012
    • William Harvey Research Institute Prize for Teaching Excellence 2011
  2. Taught Courses
    • Resistant Hypertension Course Berlin
      Germany 02/2013, 02/2014, 02/2015
  3. Recent Invited lectures
    • European Society of Hypertension – Workshop on Multidrug intolerant hypertension, 12/06/2015
    • Innovations in Hypertension, London, UK – Medical strategies for resistant hypertension, 26/06/2014
    • EuroPCR, Paris, France – Non renal targets for hypertension therapy, 20/05/2014
    • UK Kidney Week, Glasgow, UK – Overview of device therapy of Hypertension, 02/05/2014
    • ISET Conference, Miami, Florida – Newer technologies for Renal Denervation, 20/01/2014
    • ICI Meeting, Tel Aviv, Israel – Renal Denervation Update, 02/12/2013
    • BHS Meeting, London, UK – Device Management of Hypertension, 09/09/2013
    • ESC Congress, Amsterdam, Netherlands – Developing consensus on renal denervation, 01/09/2013

References

  1. Symplicity HTNI, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376(9756): 1903-9.
  2. Lobo MD. Renal sympathetic denervation: cautious optimism and careful next steps. Br J Cardiol; 2013.
  3. Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet 2015.
  4. Lobo MD, de Belder MA, Cleveland T, et al. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart 2015; 101(1): 10-6.
  5. Caulfield M, de Belder M, Cleveland T, et al. Joint UK Societies’ Consensus Summary Statement on Renal Denervation for Resistant Hypertension 2011. (accessed)
  6. Kapil V, Lobo M. Hypertension – pathogenesis, risk factors and prevention. Medicine 2014.
  7. Kapil V, Lobo MD. Clinical Considerations and the Potential for Renal Denervation. Endovascular Today, Oct 2013, 2013. (accessed).
  8. Kapil V, Jain AK, Lobo MD. Renal Sympathetic Denervation – A Review of Applications in Current Practice. Interventional Cardiology Review 2014; 9(1): 54-61.
  9. Burchell AE, Lobo MD, Sulke N, Sobotka PA, Paton JF. Arteriovenous anastomosis: is this the way to control hypertension? Hypertension 2014; 64(1): 6-12.
  10. Paton JF, Sobotka PA, Fudim M, et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 2013; 61(1): 5-13.
  11. Wolff C, Collier D, Shah M, et al. Regulation of blood flow and pressure. Advances in Experimental Medicine and Biology in press.
  12. Rajoo SG, Ng FL, Lobo M. e-Learning to facilitate preparation for prescribing skills assessment. Medical education 2013; 47(5): 520.